Qiming invests $30m in Chinese medical AI solutions player

Huimei Technology is a division of Huimei Healthcare Management Services, which was established in 2015 by Hillhouse Capital and US-based non-profit medical group Mayo Clinic. It is led by Qi Zhang, who was previously head of the algorithm team for Alibaba Group's Tmall platform.

WuXi AppTec, a local contract research outsourcing group, and Huimei Capital, an investment arm of Huimei Healthcare, also took part in the round.

The company's flagship product is Dr. Mayson, a clinical decision support system (CDSS) that helps doctors detect certain medical conditions. It relies on data sourced from more than 60 grade-three hospitals in China. There is also a team of 30 full-time doctors that help engineers design relevant algorithms.

Huimei's innovations include a smart VTE prevention and control system. It targets venous thromboembolism or blood clots that start in veins. This is the third most commonly diagnosed blood circulation disorder. According to Zhang, successful VTE diagnoses increased by 85% in a Beijing hospital within two months of launching the system.

There have been multiple PE and VC investments in businesses that use a combination of natural language processing, machine learning, and data mining to analyze healthcare data on a large scale. In addition to enabling intelligent diagnosis of medical conditions, these solutions improve the efficiency of record-keeping and data management.

In July, Tencent Holdings led a Series C round for Synyi, a Chinese AI start-up that targets hospitals. Other recipients of private funding include Miaojiankang, Airdoc, Zhiyun Health, Huiying, Taimei Medical Technology, and Beijing Infervision.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Technology
• Early-stage
• Healthcare
• China
• Qiming Venture Partners
• Hillhouse Capital Management
• artificial intelligence